You are here: Home » Reuters » News
Business Standard

Sanofi and Regeneron boost investment in cancer drug cemiplimab

Reuters  |  PARIS 

(Reuters) - France's and U.

S said on Monday they would inject an additional $1 billion in the development of cemiplimab, an that could, if successful, be used to treat a wide range of

In a statement, the two companies said they would also accelerate the co-development of dupilumab, a "multi-targeting" drug approved in the and to treat and undergoing tests to help treat asthma, nasal polyps, and

"The in cemiplimab will be increased to $1.64 billion, an increase of approximately $1 billion over the initial 2015 agreement and and will continue to equally fund cemiplimab development," the two groups said.

Cemiplimab is currently being studied as a monotherapy and in combination with other therapies in several including advanced skin cancers, non-small cell lung cancer, cervical and

"The companies expect to submit U. S. and EU for cemiplimab in in the first quarter of 2018," said.

Sanofi, whose shares have underperformed major rivals in recent years, has embarked on a strategy to rebuild a strong position in oncology.

The world's sixth largest drugmaker said last month it expected to file nine medicines for regulatory assessment by July 2019.

(Reporting by Matthias Blamont, editing by and Louise Heavens)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, January 08 2018. 19:33 IST